Citalopram ( DrugBank: Citalopram )

7 diseases

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04497168 (ClinicalTrials.gov)	April 1, 2021	29/7/2020	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Parkinson Disease	Drug: Citalopram 20mg;Drug: Placebo	University of Michigan	National Institute on Aging (NIA)	Recruiting	65 Years	N/A	All	58	Phase 2	United States
2	NCT04590612 (ClinicalTrials.gov)	January 2021	17/9/2020	Improving Quality of Life in Early Parkinson's Disease	The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients	Parkinson Disease;Depression	Drug: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet;Drug: Citalopram	Western University, Canada	NULL	Not yet recruiting	50 Years	80 Years	All	30	N/A	NULL

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00271596 (ClinicalTrials.gov)	November 2005	30/12/2005	Citalopram to Enhance Cognition in HD	A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)	Huntington Disease;Chorea;Executive Dysfunction	Drug: 20mg daily citalopram;Drug: Placebo	University of Iowa	National Institute of Neurological Disorders and Stroke (NINDS);Cure Huntington's Disease Initiative (CHDI);University of Rochester;Mayo Clinic	Completed	18 Years	75 Years	All	33	Phase 2	United States

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01436643 (ClinicalTrials.gov)	November 2011	16/9/2011	Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression	A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression	Depression;Relapsing-remitting Multiple Sclerosis	Drug: Venlafaxine;Drug: Fluoxetine;Drug: Citalopram;Drug: Fingolimod	Novartis Pharmaceuticals	NULL	Terminated	18 Years	65 Years	All	54	Phase 4	Germany

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01716221 (ClinicalTrials.gov)	October 2012	25/10/2012	An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	Friedreich Ataxia	Drug: bupropion & Citalopram;Drug: Bupropion & Placebo;Drug: Placebo & Citalopram;Drug: Placebo & Placebo	University of Colorado, Denver	NULL	Completed	N/A	N/A	Female	1	Phase 4	NULL

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01154647 (ClinicalTrials.gov)	September 2010	28/6/2010	Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes	Unraveling Impaired Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes: a Series of Experiments Targeting Brain Neurotransmission	Fatigue Syndrome, Chronic;Fibromyalgia;Arthritis, Rheumatoid	Drug: citalopram;Drug: 1 ml 0.9 % NaCl	Vrije Universiteit Brussel	Research Foundation Flanders;Universiteit Antwerpen;University Hospital, Antwerp;Artesis University College, Antwerp	Not yet recruiting	18 Years	65 Years	Female	70	N/A	Belgium

臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002288-24-NL (EUCTR)	10/08/2021	27/07/2021	Effect of citalopram on chest pain in patients with chest pain of unkown origin	Effect of citalopram on chest pain in patients with functional chest pain - Ci-FCP	Chest pain can be divided in cardiac or non-cardiac chest pain (NCCP). To establish the diagnosis NCCP, acute coronary disease has to be ruled out first. NCCP can be caused by functional chest pain (FCP). NCCP in the absence of musculoskeletal abnormalities, major esophageal motor disorders, gastroesophageal reflux or eosinophilic esophagitis is called FCP.;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Trade Name: Citalopram Product Name: Citalopram	Amsterdam UMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 4	Netherlands

臨床試験数 : 90 / 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00376051 (ClinicalTrials.gov)	September 2006	13/9/2006	Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia	Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia	Frontotemporal Dementia	Drug: Citalopram	Sunnybrook Health Sciences Centre	Alzheimer Society of Canada	Completed	18 Years	N/A	All	22	Phase 4	Canada